Products
Platform
Research
Market
Learn
IPO
Compare Tata India Pharma & Healthcare Fund vs ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund
Fund Comparison
Detailed comparison on parameters like NAV | Returns | Risk | Rating | Analysis
Fund Details
Risk | Very High | Very High |
Rating | 3.0 | 5.0 |
Min SIP Amount | ₹100 | ₹100 |
Expense Ratio | 2.1 | 1.87 |
NAV | ₹30.91 | ₹40.81 |
Fund Started | 04 Dec 2015 | 25 Jun 2018 |
Fund Size | ₹1324.90 Cr | ₹6437.36 Cr |
Exit Load | Exit load of 0.25% if redeemed within 30 days. | Exit load of 1% if redeemed within 15 days. |
Risk
Very High
Very High
Rating
3.0
5.0
Min SIP Amount
₹100
₹100
Expense Ratio
2.1
1.87
NAV
₹30.91
₹40.81
Fund Started
04 Dec 2015
25 Jun 2018
Fund Size
₹1324.90 Cr
₹6437.36 Cr
Exit Load
Exit load of 0.25% if redeemed within 30 days.
Exit load of 1% if redeemed within 15 days.
Returns
1 Year | 4.99% | 8.44% |
3 Year | 21.94% | 27.59% |
5 Year | 17.77% | 20.62% |
1 Year
4.99%
8.44%
3 Year
21.94%
27.59%
5 Year
17.77%
20.62%
Holding Analysis
Equity | 98.47% | 97.10% |
Cash | 1.53% | 2.90% |
Equity
98.47%
97.10%
Cash
1.53%
2.90%
Top Holdings
Top 10 Holdings |
|
|
Top 10 Holdings
Name | Assets |
|---|---|
Sun Pharmaceutical Industries Ltd. | 9.59% |
Apollo Hospitals Enterprise Ltd. | 5.13% |
Healthcare Global Enterprises Ltd. | 4.96% |
Lupin Ltd. | 4.90% |
Max Healthcare Institute Ltd. | 4.71% |
Torrent Pharmaceuticals Ltd. | 4.52% |
Alkem Laboratories Ltd. | 4.42% |
Abbott India Ltd. | 4.02% |
Cipla Ltd. | 3.92% |
Ipca Laboratories Ltd. | 3.56% |
Name | Assets |
|---|---|
Sun Pharmaceutical Industries Ltd. | 11.88% |
Dr. Reddy's Laboratories Ltd. | 9.42% |
Divi's Laboratories Ltd. | 8.50% |
Aurobindo Pharma Ltd. | 7.62% |
Cipla Ltd. | 6.61% |
Lupin Ltd. | 5.40% |
Alkem Laboratories Ltd. | 3.98% |
Biocon Ltd. | 3.28% |
Mankind Pharma Ltd. | 2.79% |
Zydus Lifesciences Ltd. | 2.67% |
Fund Manager
Name | Meeta Shetty | Dharmesh Kakkad |
Start Date | 11 Nov 2024 | 23 Feb 2021 |
Name
Meeta Shetty
Dharmesh Kakkad
Start Date
11 Nov 2024
23 Feb 2021
About Fund
Description | The scheme seeks long term capital appreciation by investing atleast 80% of it's net assets in equity/equity related instruments of the companies in the pharma & healthcare sectors in India. | The scheme seeks to generate long-term capital appreciation by creating a portfolio that is invested in equity and equity related securities of pharma, healthcare, hospitals, diagnostics, wellness and allied companies. |
Launch Date | 04 Dec 2015 | 25 Jun 2018 |
Description
The scheme seeks long term capital appreciation by investing atleast 80% of it's net assets in equity/equity related instruments of the companies in the pharma & healthcare sectors in India.
The scheme seeks to generate long-term capital appreciation by creating a portfolio that is invested in equity and equity related securities of pharma, healthcare, hospitals, diagnostics, wellness and allied companies.
Launch Date
04 Dec 2015
25 Jun 2018